Wednesday, July 13, 2016
Today's must-read reports are for Bristol-Myers (BMY - Free Report) , ConocoPhillips (COP - Free Report) and eBay (EBAY - Free Report) .
Bristol-Myers shares are up +11% year-to-date, with this Zacks Rank # 2 (Buy) rated stock getting a boost when its cancer drug, Opdivo, became the first PD-1 immune checkpoint inhibitor to gain regulatory approval anywhere in the world. The analyst likes the company’s higher guidance for 2016 and its concerted efforts to develop its pipeline are also encouraging. (You can read the full research report on BMY here.)
Zacks Rank # 2 (Buy) rated ConocoPhillips shares have been laggards lately, but the analyst likes ConocoPhillips’ greater focus on North America, Australia and Asia which is expected to improve its risk profile. Additionally, ConocoPhillips’ initiatives towards liquids-rich plays are starting to bear fruit buoyed by the Eagle Ford, Bakken and Permian plays. (You can read the full research report on COP here.)
Despite lingering in the red year-to-date, shares of eBay have gained more than 5% over the last one month. The analyst likes the Zacks Rank # 2 (Buy) rated stock’s opportunities in the fast-growing mobile space, international expansion and a strong balance sheet. The company's concerted efforts to squeeze additional costs out of its operations hold the promise of a boost to margins in the coming quarters. (You can read the full research report on EBAY here.)
Other noteworthy reports we are featuring today include Pepsi (PEP - Free Report) , Viacom and Suncor Energy (SU - Free Report) .
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premiumsubscribers and manages the Zacks Focus Listand Top 10portfolios. If you want an email notification each time Sheraz publishes a new article, please click here
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Wednesday, July 13, 2016
Today's must-read reports are for Bristol-Myers (BMY - Free Report) , ConocoPhillips (COP - Free Report) and eBay (EBAY - Free Report) .
Bristol-Myers shares are up +11% year-to-date, with this Zacks Rank # 2 (Buy) rated stock getting a boost when its cancer drug, Opdivo, became the first PD-1 immune checkpoint inhibitor to gain regulatory approval anywhere in the world. The analyst likes the company’s higher guidance for 2016 and its concerted efforts to develop its pipeline are also encouraging. (You can read the full research report on BMY here.)
Zacks Rank # 2 (Buy) rated ConocoPhillips shares have been laggards lately, but the analyst likes ConocoPhillips’ greater focus on North America, Australia and Asia which is expected to improve its risk profile. Additionally, ConocoPhillips’ initiatives towards liquids-rich plays are starting to bear fruit buoyed by the Eagle Ford, Bakken and Permian plays. (You can read the full research report on COP here.)
Despite lingering in the red year-to-date, shares of eBay have gained more than 5% over the last one month. The analyst likes the Zacks Rank # 2 (Buy) rated stock’s opportunities in the fast-growing mobile space, international expansion and a strong balance sheet. The company's concerted efforts to squeeze additional costs out of its operations hold the promise of a boost to margins in the coming quarters. (You can read the full research report on EBAY here.)
Other noteworthy reports we are featuring today include Pepsi (PEP - Free Report) , Viacom and Suncor Energy (SU - Free Report) .
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premiumsubscribers and manages the Zacks Focus Listand Top 10portfolios. If you want an email notification each time Sheraz publishes a new article, please click here
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on COP - FREE
Get the latest research report on EBAY - FREE
Get the latest research report on PEP - FREE
Get the latest research report on SU - FREE